InfuPharma Targets Insurer For Avastin Defense

Law360, New York (April 23, 2012, 7:54 PM EDT) -- InfuPharma LLC on Thursday dragged a Chartis Inc. affiliate into a dispute with another insurer over defense of the pharmaceutical distributor in suits alleging InfuPharma improperly compounded Genentech Inc.'s cancer drug Avastin, leading to eye injury and blindness.

In a third-party complaint filed in the Southern District of Florida, InfuPharma said Chartis affiliate Commerce and Industry Insurance Co. has a duty to defend it in the underlying suits under a policy that provides $2 million in coverage for "products completed operations" and another $2 million of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.